Randomized Phase III Study of Zanzalintinib ± Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) versus Placebo in Participants with Stage II/III Colorectal Cancer with Molecular Residual Disease Following Definitive Therapy
Clinical Trial Information
Trial Contact: Clinical Trial Referral Office
Trial Phone: 321-841-7246
Principal Investigator: Raji Shameem, MD
Phase: III
Age Group: ADULTOLDER_ADULT
ClinicalTrials.gov ID: NCT07750158
Objective
The purpose of this study is to learn whether zanzalintinib given with MK-3475A, or zanzalintinib given alone, is better than a placebo (an inactive substance) at delaying or preventing the cancer from coming back after treatment. Researchers will compare each treatment approach with placebo to determine which is more effective.